A special Sunday edition of BioBrief previewing the biotech and biopharma catalysts to watch for the week ahead.

In this Week Ahead by BioBrief:

• REGENXBIO / RGX-202 — The main event is Thursday’s pivotal Duchenne muscular dystrophy gene-therapy readout, with investors watching microdystrophin expression, safety, functional context, and the possible 2026 B L A path.
• ASGCT 2026 — The American Society of Gene and Cell Therapy annual meeting runs Monday through Friday, putting AAV delivery, genome editing, cell therapy, rare disease, CNS delivery, and in vivo engineering back in focus.
• Tenaya / TN-401 — Tenaya is expected to present new Phase 1b/2 data for its cardiac gene therapy in PKP2-associated arrhythmogenic right ventricular cardiomyopathy.
• Biot ...